Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17639442 | Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use | Final Rejection | UNIVERSITY OF WASHINGTON |
| 17050115 | INDICATOR BACTERIOPHAGE FOR SELECTING AND MONITORING FOR EFFICACY OF THERAPEUTICS AND METHODS FOR USING SAME | Non-Final OA | LABORATORY CORPORATION OF AMERICA HOLDINGS |
| 17968115 | VIRUS-LIKE PARTICLE WITH EFFICIENT EPITOPE DISPLAY | Non-Final OA | University of Copenhagen |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | Non-Final OA | PFIZER INC. |
| 18034720 | GENE SHUFFLED LYSSAVIRUS VACCINE | Non-Final OA | Thomas Jefferson University |
| 18318842 | DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 18659639 | EPSTEIN-BARR VIRUS VACCINES | Final Rejection | The USA, as represented by the Secretary, Dept, of Health and Human Services |
| 17761459 | HUMAN RESPIRATORY SYNCYTIAL VIRUS STRAIN AND ITS USE | Final Rejection | UNIVERSITEIT ANTWERPEN |
| 18024868 | VACCINE FOR VIRAL PATHOGENS | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 17802936 | COMPOSITIONS COMPRISING SELF-ASSEMBLING VACCINES AND METHODS OF USING THE SAME | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18418050 | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETES | Non-Final OA | Vactech Oy |
| 18044245 | FUSION PROTEIN COMPRISING CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN AND NUCLEOCAPSID PROTEIN, AND USE THEREOF | Non-Final OA | GI CELL, INC. |
| 17841267 | COMBINATIONS OF FLAVIVIRUS PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF | Non-Final OA | LA JOLLA INSTITUTE FOR IMMUNOLOGY |
| 18359526 | DNA-STABILISED METAL CLUSTER BASED NUCLEIC ACID-SENSOR WITH DISTINCT EMISSION COLOUR AND INTENSITY CHANGE UPON TARGET RECOGNITION | Non-Final OA | Universiteit Leiden |
| 17621125 | ATTENUATED DENGUE VIRUSES | Non-Final OA | CODAGENIX INC. |
| 18261811 | INFORMATION PROVISION METHOD FOR EXAMINING ACTIVE IMMUNITY BY USING PRODUCTION OF NEUTRALIZING ANTIBODIES AND INTERFERON GAMMA | Non-Final OA | BODITECH MED INC. |
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | Non-Final OA | Children's Hospital Medical Center |
| 17907424 | DEFECTIVE INTERFERING VIRAL GENOMES | Non-Final OA | INSTITUT PASTEUR |
| 17912563 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | Final Rejection | Biohaven Therapeutics Ltd. |
| 18266486 | USE OF VACCINE COMPOSITIONS BASED ON SARS-COV-2 RECEPTOR BINDING DOMAIN IN DELIVERING PROTECTIVE IMMUNITY | Non-Final OA | Centro de Inmunología Molecular |
| 18265008 | DIAGNOSTIC TESTING | Non-Final OA | PARAYTEC LTD |
| 18038673 | YEAST-BASED EXPRESSION OF THERAPEUTIC PROTEINS IN VIVO | Non-Final OA | ESPEROVAX INC. |
| 18020659 | PROTEINS, POLYNUCLEOTIDES, AND METHODS FOR TREATING CORONAVIRUS INFECTION | Non-Final OA | WESTPORT BIO, LLC |
| 18004517 | ENHANCING IMMUNE RESPONSES THROUGH TARGETED ANTIGEN EXPRESSION | Non-Final OA | PhageNova Bio, Inc. |
| 18009714 | VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | Non-Final OA | Sichuan Clover Biopharmaceuticals, Inc. |
| 17615661 | SMALLPOX VACCINE AND STEM CELLS FOR TREATMENT OF DISEASE | Final Rejection | IMMUNOLUX INTERNATIONAL CORP. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy